Bone Biologics annual ebitda
2014
2015
2016
2017
2018
2019
2022
2023
2024
2025
Bone Biologics EBITDA Growth & History (BBLG)
Bone Biologics's calculated EBITDA was −$3.2M for fiscal 2025.
View full Bone Biologics company overviewBone Biologics annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$3.2M | $984,219 | — |
| 2024 | 2024-12-31 | −$4.2M | $5.2M | — |
| 2023 | 2023-12-31 | −$9.4M | −$5.8M | — |
| 2022 | 2022-12-31 | −$3.7M | — | — |
| 2019 | 2019-12-31 | −$2.4M | $343,409 | — |
| 2018 | 2018-12-31 | −$2.8M | −$164,297 | — |
| 2017 | 2017-12-31 | −$2.6M | $17.8M | — |
| 2016 | 2016-12-31 | −$20.4M | −$8.4M | — |
| 2015 | 2015-12-31 | −$12.0M | −$9.0M | — |
| 2014 | 2014-12-31 | −$3.0M | — | — |
Bone Biologics quarterly ebitda
Q1.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$808,106 | −$60,031 | — |
| Q1 2026 | 2026-03-31 | −$805,054 | $233,432 | — |
| Q4 2025 | 2025-12-31 | −$733,105 | — | — |
| Q3 2025 | 2025-09-30 | −$715,274 | — | — |
| Q2 2025 | 2025-06-30 | −$748,075 | — | — |
| Q1 2025 | 2025-03-31 | −$1.0M | — | — |
| Q4 2019 | 2019-12-31 | −$277,630 | $961,152 | — |
| Q3 2019 | 2019-09-30 | −$301,310 | −$706,125 | — |
| Q2 2019 | 2019-06-30 | −$679,231 | $180,895 | — |
| Q1 2019 | 2019-03-31 | −$1.2M | −$92,513 | — |
| Q4 2018 | 2018-12-31 | −$1.2M | $71,799 | — |
| Q3 2018 | 2018-09-30 | $404,815 | $1.5M | — |
| Q2 2018 | 2018-06-30 | −$860,126 | −$2.8M | — |
| Q1 2018 | 2018-03-31 | −$1.1M | $1.1M | — |
| Q4 2017 | 2017-12-31 | −$1.3M | $1.8M | — |
| Q3 2017 | 2017-09-30 | −$1.1M | $2.7M | — |
| Q2 2017 | 2017-06-30 | $2.0M | $6.3M | — |
| Q1 2017 | 2017-03-31 | −$2.2M | $6.9M | — |
| Q4 2016 | 2016-12-31 | −$3.1M | $4.5M | — |
| Q3 2016 | 2016-09-30 | −$3.9M | −$889,495 | — |
| Q2 2016 | 2016-06-30 | −$4.3M | −$3.8M | — |
| Q1 2016 | 2016-03-31 | −$9.1M | −$8.2M | — |
| Q4 2015 | 2015-12-31 | −$7.6M | — | — |
| Q3 2015 | 2015-09-30 | −$3.0M | — | — |
| Q2 2015 | 2015-06-30 | −$510,007 | — | — |
| Q1 2015 | 2015-03-31 | −$922,849 | −$749,084 | — |
| Q1 2014 · Mar 31 | 2014-03-31 | −$173,765 | — | — |
Bone Biologics ebitda trends
Between the periods ended 2014-12-31 and 2025-12-31, Bone Biologics's ebitda decreased from −$3.0M to −$3.2M, a change of −$224,618. The latest reported quarter, Q2 2026, shows −$808,106.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Bone Biologics source filings ↗